This indicates that regardless of the mechanisms leading to LIFR downregulated in breast tumors and bone DTCs, HDAC inhibitors may still be used to induce tumor dormancy to reduce breast cancer recurrence and improve prognosis. This evidence concerns the gene LIFR and breast carcinoma.